|
21.09.2024 10:15:44
|
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks
(RTTNews) - Zevra Therapeutics Inc. (ZVRA) made headlines yesterday with a landmark FDA approval for its innovative drug, MIPLYFFA, in the treatment of Niemann-Pick disease type C. The regulatory development not only offers new hope for patients with this ultra-rare and progressive neurodegenerative disease but has also propelled Zevra shares to a new 52-week high.
In addition to ZVRA, a couple of stocks we featured on our site also touched new 52-week highs yesterday.
*Last Closing Price refers to the stock's closing price on Sep.20, 2024.
Ticker | Published Date | Published Price | Maximum Price Since Publication | *Last Closing Price | Maximum Gain % |
|---|---|---|---|---|---|
Aug.26, 2024 | $7.21 | $8.81 | $8.06 | 22% | |
June 3, 2022 | $12.66 | $88.17 | $86.61 | 596% | |
Sep.4, 2024 | $3.21 | $4.57 | $4.40 | 42% | |
Feb.13, 2024 | $13.32 | $21.67 | $20.79 | 62% | |
Feb.15, 2024 | $5.36 | $20.16 | $19.98 | 276% | |
Oct.9, 2023 | $6.38 | $13.23 | $13.09 | 107% | |
Feb.7, 2023 | $12.38 | $36.33 | $35.68 | 193% | |
Aug.14, 2024 | $8.91 | $15.26 | $15.21 | 71% |
Related Reading
EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot?
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Arcellx Inc Registered Shsmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Arcellx Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
| ADMA Biologics Inc | 21,30 | -0,33% |
|
| Arcellx Inc Registered Shs | 87,22 | 0,00% |
|
| Catalyst Pharmaceutical Partners Inc. | 20,02 | -0,30% |
|
| Pennant Group Inc Registered Shs When Issued | 28,00 | -5,41% |
|
| Travere Thereapeutics Inc Registered Shs | 18,26 | 2,24% |
|
| Zevra Therapeutics Inc Registered Shs | 8,60 | 2,99% |
|
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.